ID   CAH9_HUMAN              Reviewed;         459 AA.
AC   Q16790; Q5T4R1;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2005, sequence version 2.
DT   10-MAY-2017, entry version 165.
DE   RecName: Full=Carbonic anhydrase 9;
DE            EC=4.2.1.1;
DE   AltName: Full=Carbonate dehydratase IX;
DE   AltName: Full=Carbonic anhydrase IX;
DE            Short=CA-IX;
DE            Short=CAIX;
DE   AltName: Full=Membrane antigen MN;
DE   AltName: Full=P54/58N;
DE   AltName: Full=Renal cell carcinoma-associated antigen G250;
DE            Short=RCC-associated antigen G250;
DE   AltName: Full=pMW1;
DE   Flags: Precursor;
GN   Name=CA9; Synonyms=G250, MN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND VARIANT MET-33.
RC   TISSUE=Carcinoma;
RX   PubMed=8084592;
RA   Pastorek J., Pastorekova S., Callebaut I., Mornon J.-P., Zelnik V.,
RA   Opavsky R., Zat'Ovicova M., Liao S., Portetelle D., Stanbridge E.J.,
RA   Zavada J., Burny A., Kettmann R.;
RT   "Cloning and characterization of MN, a human tumor-associated protein
RT   with a domain homologous to carbonic anhydrase and a putative helix-
RT   loop-helix DNA binding segment.";
RL   Oncogene 9:2877-2888(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10709109;
RX   DOI=10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q;
RA   Grabmaier K., Vissers J.L.M., De Weijert M.C.A.,
RA   Oosterwijk-Wakka J.C., Van Bokhoven A., Brakenhoff R.H., Noessner E.,
RA   Mulders P.A., Merkx G., Figdor C.G., Adema G.J., Oosterwijk E.;
RT   "Molecular cloning and immunogenicity of renal cell carcinoma-
RT   associated antigen G250.";
RL   Int. J. Cancer 85:865-870(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-33.
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 38-52.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=1312272; DOI=10.1016/0042-6822(92)90464-Z;
RA   Pastorekova S., Zavadova Z., Kostal M., Babusikova O., Zavada J.;
RT   "A novel quasi-viral agent, MaTu, is a two-component system.";
RL   Virology 187:620-626(1992).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=8486430; DOI=10.1002/ijc.2910540218;
RA   Zavada J., Zavadova Z., Pastorekova S., Ciampor F., Pastorek J.,
RA   Zelnik V.;
RT   "Expression of MaTu-MN protein in human tumor cultures and in clinical
RT   specimens.";
RL   Int. J. Cancer 54:268-274(1993).
RN   [9]
RP   PHOSPHORYLATION AT TYR-449.
RX   PubMed=16310354; DOI=10.1016/j.ejca.2005.09.011;
RA   Dorai T., Sawczuk I.S., Pastorek J., Wiernik P.H., Dutcher J.P.;
RT   "The role of carbonic anhydrase IX overexpression in kidney cancer.";
RL   Eur. J. Cancer 41:2935-2947(2005).
RN   [10]
RP   ENZYME REGULATION.
RX   PubMed=17705204; DOI=10.1002/anie.200701189;
RA   Koehler K., Hillebrecht A., Schulze Wischeler J., Innocenti A.,
RA   Heine A., Supuran C.T., Klebe G.;
RT   "Saccharin inhibits carbonic anhydrases: possible explanation for its
RT   unpleasant metallic aftertaste.";
RL   Angew. Chem. Int. Ed. Engl. 46:7697-7699(2007).
RN   [11]
RP   ENZYME REGULATION.
RX   PubMed=17314045; DOI=10.1016/j.bmcl.2007.01.113;
RA   Temperini C., Innocenti A., Guerri A., Scozzafava A., Rusconi S.,
RA   Supuran C.T.;
RT   "Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-
RT   ray crystal structure of the antiviral drug foscarnet complexed to
RT   human carbonic anhydrase I.";
RL   Bioorg. Med. Chem. Lett. 17:2210-2215(2007).
RN   [12]
RP   FUNCTION, SUBUNIT, INDUCTION, GLYCOSYLATION AT THR-115 AND ASN-346,
RP   AND DISULFIDE BONDS.
RX   PubMed=18703501; DOI=10.1074/jbc.M800938200;
RA   Hilvo M., Baranauskiene L., Salzano A.M., Scaloni A., Matulis D.,
RA   Innocenti A., Scozzafava A., Monti S.M., Di Fiore A., De Simone G.,
RA   Lindfors M., Janis J., Valjakka J., Pastorekova S., Pastorek J.,
RA   Kulomaa M.S., Nordlund H.R., Supuran C.T., Parkkila S.;
RT   "Biochemical characterization of CA IX, one of the most active
RT   carbonic anhydrase isozymes.";
RL   J. Biol. Chem. 283:27799-27809(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   ENZYME REGULATION.
RX   PubMed=19186056; DOI=10.1016/j.bmcl.2009.01.038;
RA   Crocetti L., Maresca A., Temperini C., Hall R.A., Scozzafava A.,
RA   Muehlschlegel F.A., Supuran C.T.;
RT   "A thiabendazole sulfonamide shows potent inhibitory activity against
RT   mammalian and nematode alpha-carbonic anhydrases.";
RL   Bioorg. Med. Chem. Lett. 19:1371-1375(2009).
RN   [15]
RP   ENZYME REGULATION.
RX   PubMed=19206230; DOI=10.1021/ja809683v;
RA   Maresca A., Temperini C., Vu H., Pham N.B., Poulsen S.-A.,
RA   Scozzafava A., Quinn R.J., Supuran C.T.;
RT   "Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a
RT   new class of suicide inhibitors.";
RL   J. Am. Chem. Soc. 131:3057-3062(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 83-91 IN COMPLEX WITH
RP   SPECIFIC ANTIBODIES.
RX   PubMed=18041760; DOI=10.1002/prot.21821;
RA   Kral V., Mader P., Collard R., Fabry M., Horejsi M., Rezacova P.,
RA   Kozisek M., Zavada J., Sedlacek J., Rulisek L., Brynda J.;
RT   "Stabilization of antibody structure upon association to a human
RT   carbonic anhydrase IX epitope studied by X-ray crystallography,
RT   microcalorimetry, and molecular dynamics simulations.";
RL   Proteins 71:1275-1287(2008).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 137-391 IN COMPLEX WITH ZINC
RP   ION AND THE INHIBITOR ACETAZOLAMIDE, GLYCOSYLATION AT ASN-346,
RP   DISULFIDE BOND, SUBUNIT, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19805286; DOI=10.1073/pnas.0908301106;
RA   Alterio V., Hilvo M., Di Fiore A., Supuran C.T., Pan P., Parkkila S.,
RA   Scaloni A., Pastorek J., Pastorekova S., Pedone C., Scozzafava A.,
RA   Monti S.M., De Simone G.;
RT   "Crystal structure of the catalytic domain of the tumor-associated
RT   human carbonic anhydrase IX.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:16233-16238(2009).
CC   -!- FUNCTION: Reversible hydration of carbon dioxide. Participates in
CC       pH regulation. May be involved in the control of cell
CC       proliferation and transformation. Appears to be a novel specific
CC       biomarker for a cervical neoplasia. {ECO:0000269|PubMed:18703501}.
CC   -!- CATALYTIC ACTIVITY: H(2)CO(3) = CO(2) + H(2)O.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:19805286};
CC   -!- ENZYME REGULATION: Inhibited by coumarins, saccharin, sulfonamide
CC       derivatives such as acetazolamide (AZA) and Foscarnet
CC       (phosphonoformate trisodium salt). {ECO:0000269|PubMed:17314045,
CC       ECO:0000269|PubMed:17705204, ECO:0000269|PubMed:19186056,
CC       ECO:0000269|PubMed:19206230}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 6.5. {ECO:0000269|PubMed:19805286};
CC   -!- SUBUNIT: Forms oligomers linked by disulfide bonds.
CC       {ECO:0000269|PubMed:18041760, ECO:0000269|PubMed:18703501,
CC       ECO:0000269|PubMed:19805286}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:8486430}.
CC       Nucleus, nucleolus {ECO:0000269|PubMed:8486430}. Cell membrane
CC       {ECO:0000269|PubMed:8486430}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:8486430}. Cell projection, microvillus
CC       membrane {ECO:0000269|PubMed:8486430}; Single-pass type I membrane
CC       protein {ECO:0000269|PubMed:8486430}. Note=Found on the surface
CC       microvilli and in the nucleus, particularly in nucleolus.
CC   -!- TISSUE SPECIFICITY: Expressed primarily in carcinoma cells lines.
CC       Expression is restricted to very few normal tissues and the most
CC       abundant expression is found in the epithelial cells of gastric
CC       mucosa.
CC   -!- INDUCTION: By hypoxia. {ECO:0000269|PubMed:18703501}.
CC   -!- PTM: Asn-346 bears high-mannose type glycan structures.
CC   -!- SIMILARITY: Belongs to the alpha-carbonic anhydrase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X66839; CAA47315.1; -; mRNA.
DR   EMBL; AJ010588; CAB82444.1; -; mRNA.
DR   EMBL; AL133410; CAI10985.1; -; Genomic_DNA.
DR   EMBL; AL357874; CAI10985.1; JOINED; Genomic_DNA.
DR   EMBL; AL357874; CAI13455.1; -; Genomic_DNA.
DR   EMBL; AL133410; CAI13455.1; JOINED; Genomic_DNA.
DR   EMBL; CH471071; EAW58359.1; -; Genomic_DNA.
DR   EMBL; BC014950; AAH14950.1; -; mRNA.
DR   CCDS; CCDS6585.1; -.
DR   PIR; I38013; I38013.
DR   RefSeq; NP_001207.2; NM_001216.2.
DR   UniGene; Hs.63287; -.
DR   PDB; 2HKF; X-ray; 2.01 A; P=83-91.
DR   PDB; 3IAI; X-ray; 2.20 A; A/B/C/D=137-391.
DR   PDB; 5DVX; X-ray; 1.60 A; A/B=140-399.
DR   PDB; 5FL4; X-ray; 1.82 A; A/B/C/D=137-391.
DR   PDB; 5FL5; X-ray; 2.05 A; A/B/C/D=137-391.
DR   PDB; 5FL6; X-ray; 1.95 A; A/B/C/D=137-391.
DR   PDBsum; 2HKF; -.
DR   PDBsum; 3IAI; -.
DR   PDBsum; 5DVX; -.
DR   PDBsum; 5FL4; -.
DR   PDBsum; 5FL5; -.
DR   PDBsum; 5FL6; -.
DR   ProteinModelPortal; Q16790; -.
DR   SMR; Q16790; -.
DR   BioGrid; 107223; 30.
DR   DIP; DIP-48973N; -.
DR   IntAct; Q16790; 1.
DR   STRING; 9606.ENSP00000367608; -.
DR   BindingDB; Q16790; -.
DR   ChEMBL; CHEMBL3594; -.
DR   DrugBank; DB00562; Benzthiazide.
DR   DrugBank; DB08846; Ellagic Acid.
DR   DrugBank; DB00999; Hydrochlorothiazide.
DR   DrugBank; DB00774; Hydroflumethiazide.
DR   DrugBank; DB05304; WX-G250.
DR   DrugBank; DB00909; Zonisamide.
DR   iPTMnet; Q16790; -.
DR   PhosphoSitePlus; Q16790; -.
DR   BioMuta; CA9; -.
DR   DMDM; 83300925; -.
DR   MaxQB; Q16790; -.
DR   PaxDb; Q16790; -.
DR   PeptideAtlas; Q16790; -.
DR   PRIDE; Q16790; -.
DR   DNASU; 768; -.
DR   Ensembl; ENST00000378357; ENSP00000367608; ENSG00000107159.
DR   GeneID; 768; -.
DR   KEGG; hsa:768; -.
DR   UCSC; uc003zxo.5; human.
DR   CTD; 768; -.
DR   DisGeNET; 768; -.
DR   GeneCards; CA9; -.
DR   H-InvDB; HIX0008019; -.
DR   HGNC; HGNC:1383; CA9.
DR   HPA; CAB005100; -.
DR   HPA; CAB017107; -.
DR   HPA; HPA055207; -.
DR   MIM; 603179; gene.
DR   neXtProt; NX_Q16790; -.
DR   OpenTargets; ENSG00000107159; -.
DR   PharmGKB; PA25998; -.
DR   eggNOG; KOG0382; Eukaryota.
DR   eggNOG; COG3338; LUCA.
DR   GeneTree; ENSGT00760000118915; -.
DR   HOGENOM; HOG000112637; -.
DR   HOVERGEN; HBG002837; -.
DR   InParanoid; Q16790; -.
DR   KO; K01672; -.
DR   OMA; SRYFRYE; -.
DR   OrthoDB; EOG091G0XFM; -.
DR   PhylomeDB; Q16790; -.
DR   TreeFam; TF316425; -.
DR   BRENDA; 4.2.1.1; 2681.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1475029; Reversible hydration of carbon dioxide.
DR   SIGNOR; Q16790; -.
DR   EvolutionaryTrace; Q16790; -.
DR   GeneWiki; Carbonic_anhydrase_9; -.
DR   GenomeRNAi; 768; -.
DR   PRO; PR:Q16790; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000107159; -.
DR   CleanEx; HS_CA9; -.
DR   ExpressionAtlas; Q16790; baseline and differential.
DR   Genevisible; Q16790; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0031528; C:microvillus membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004089; F:carbonate dehydratase activity; TAS:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0015701; P:bicarbonate transport; TAS:Reactome.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; IEA:Ensembl.
DR   GO; GO:0006730; P:one-carbon metabolic process; IEA:InterPro.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0046903; P:secretion; IEA:Ensembl.
DR   Gene3D; 3.10.200.10; -; 1.
DR   InterPro; IPR018429; CA9.
DR   InterPro; IPR001148; Carbonic_anhydrase_a.
DR   InterPro; IPR023561; Carbonic_anhydrase_a-class.
DR   InterPro; IPR018338; Carbonic_anhydrase_a-class_CS.
DR   PANTHER; PTHR18952; PTHR18952; 1.
DR   PANTHER; PTHR18952:SF161; PTHR18952:SF161; 1.
DR   Pfam; PF00194; Carb_anhydrase; 1.
DR   SMART; SM01057; Carb_anhydrase; 1.
DR   SUPFAM; SSF51069; SSF51069; 1.
DR   PROSITE; PS00162; ALPHA_CA_1; 1.
DR   PROSITE; PS51144; ALPHA_CA_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cell projection; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Lyase;
KW   Membrane; Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix; Zinc.
FT   SIGNAL        1     37       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        38    459       Carbonic anhydrase 9.
FT                                /FTId=PRO_0000004243.
FT   TOPO_DOM     38    414       Extracellular.
FT   TRANSMEM    415    435       Helical. {ECO:0000255}.
FT   TOPO_DOM    436    459       Cytoplasmic.
FT   DOMAIN      139    390       Alpha-carbonic anhydrase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01134}.
FT   REGION       38    112       Proteoglycan-like (PG).
FT   REGION      113    414       Catalytic.
FT   REGION      332    333       Substrate binding.
FT                                {ECO:0000250|UniProtKB:P00918}.
FT   ACT_SITE    200    200       Proton acceptor.
FT                                {ECO:0000250|UniProtKB:P00918}.
FT   METAL       226    226       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:19805286}.
FT   METAL       228    228       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:19805286}.
FT   METAL       251    251       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:19805286}.
FT   MOD_RES     449    449       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:16310354}.
FT   CARBOHYD    115    115       O-linked (GlcNAc...) threonine.
FT                                {ECO:0000269|PubMed:18703501}.
FT   CARBOHYD    346    346       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:18703501,
FT                                ECO:0000269|PubMed:19805286}.
FT   DISULFID    156    336       {ECO:0000269|PubMed:19805286}.
FT   DISULFID    174    174       Interchain.
FT                                {ECO:0000305|PubMed:19805286}.
FT   VARIANT      33     33       V -> M (in dbSNP:rs2071676).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8084592}.
FT                                /FTId=VAR_010787.
FT   VARIANT     326    326       Q -> R (in dbSNP:rs3829078).
FT                                /FTId=VAR_020049.
FT   TURN        137    139       {ECO:0000244|PDB:3IAI}.
FT   STRAND      145    147       {ECO:0000244|PDB:5FL4}.
FT   HELIX       149    152       {ECO:0000244|PDB:5DVX}.
FT   HELIX       154    157       {ECO:0000244|PDB:5DVX}.
FT   HELIX       168    170       {ECO:0000244|PDB:5DVX}.
FT   STRAND      171    173       {ECO:0000244|PDB:5FL6}.
FT   STRAND      181    184       {ECO:0000244|PDB:5DVX}.
FT   STRAND      193    197       {ECO:0000244|PDB:5DVX}.
FT   STRAND      202    205       {ECO:0000244|PDB:5DVX}.
FT   STRAND      211    215       {ECO:0000244|PDB:5DVX}.
FT   STRAND      218    229       {ECO:0000244|PDB:5DVX}.
FT   STRAND      238    241       {ECO:0000244|PDB:5DVX}.
FT   STRAND      247    256       {ECO:0000244|PDB:5DVX}.
FT   HELIX       262    265       {ECO:0000244|PDB:5DVX}.
FT   STRAND      271    281       {ECO:0000244|PDB:5DVX}.
FT   HELIX       287    293       {ECO:0000244|PDB:5DVX}.
FT   TURN        294    296       {ECO:0000244|PDB:5FL4}.
FT   HELIX       297    299       {ECO:0000244|PDB:5DVX}.
FT   STRAND      305    308       {ECO:0000244|PDB:5DVX}.
FT   HELIX       313    316       {ECO:0000244|PDB:5DVX}.
FT   STRAND      324    330       {ECO:0000244|PDB:5DVX}.
FT   STRAND      338    347       {ECO:0000244|PDB:5DVX}.
FT   STRAND      349    351       {ECO:0000244|PDB:5DVX}.
FT   HELIX       353    361       {ECO:0000244|PDB:5DVX}.
FT   STRAND      387    390       {ECO:0000244|PDB:5DVX}.
SQ   SEQUENCE   459 AA;  49698 MW;  BA67195483F0F5CE CRC64;
     MAPLCPSPWL PLLIPAPAPG LTVQLLLSLL LLVPVHPQRL PRMQEDSPLG GGSSGEDDPL
     GEEDLPSEED SPREEDPPGE EDLPGEEDLP GEEDLPEVKP KSEEEGSLKL EDLPTVEAPG
     DPQEPQNNAH RDKEGDDQSH WRYGGDPPWP RVSPACAGRF QSPVDIRPQL AAFCPALRPL
     ELLGFQLPPL PELRLRNNGH SVQLTLPPGL EMALGPGREY RALQLHLHWG AAGRPGSEHT
     VEGHRFPAEI HVVHLSTAFA RVDEALGRPG GLAVLAAFLE EGPEENSAYE QLLSRLEEIA
     EEGSETQVPG LDISALLPSD FSRYFQYEGS LTTPPCAQGV IWTVFNQTVM LSAKQLHTLS
     DTLWGPGDSR LQLNFRATQP LNGRVIEASF PAGVDSSPRA AEPVQLNSCL AAGDILALVF
     GLLFAVTSVA FLVQMRRQHR RGTKGGVSYR PAEVAETGA
//
